Compare Cytokinetics Inc (CYTK) vs Fox Corp Class B (FOX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Fox Corp Class B — how do they compare? Cytokinetics Inc trades at $62.9 (market cap $8.62B), while Fox Corp Class B trades at $56.1 (market cap $25.36B). The key difference: Fox Corp Class B is far larger — about 2.9× Cytokinetics Inc's market cap, and Fox Corp Class B pays a 1.02% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Fox Corp Class B for 75 Days on average.
| CYTK | FOX | |
|---|---|---|
Market Cap | $8.62B | $25.36B |
Volume | 2,594,626 | 886,620 |
Sector | Health | Media |
52-Week High | $87.26 | $67.76 |
52-Week Low | $54.76 | $44.39 |
Typical Hold Time | 19 Days | 75 Days |
Enterprise Value | $8.72B | $28.72B |
Dividend Yield | — | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
FOX trades at $55.98, up 0.72% today, with a bearish technical signal but strong fundamentals. Recent earnings consistently beat estimates, with Q2 2026 EPS of $1.79 surpassing the $1.44 expectation. Revenue grew to $16.30B in 2025, and net income margin expanded to 13.88%. The company maintains solid cash flow, with operating cash flow of $3.32B in 2025. A dividend of $0.29 is scheduled for payment on September 23, 2026.
The stock presents a value opportunity with a P/E of 14.85 below industry averages, supported by analyst consensus price target of $84.75 implying 51% upside. Risks include a projected net cash flow decline to -$1.1B in 2026 and bearish technical indicators. Investor sentiment is mixed amid ongoing regulatory scrutiny of acquisitions, as noted in recent news.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →
